Big Pharma Lashes Out At Generic Competition

Law360, New York (June 29, 2006, 12:00 AM EDT) -- Brand-name drug manufacturers, facing potentially billions of dollars in losses when their patent protection on drugs expires, are attempting to protect their market shares by slashing prices to undercut the generic competition--a move that has some accusing the pharmaceutical companies of predatory pricing.

Just one week after Merck & Co. offered to sell cholesterol drug Zocor to insurance providers at a lower price than Teva Pharmaceuticals’ generic version, Pfizer Inc. said Thursday it plans to introduce a heavily discounted copycat version of antidepressant Zoloft.

Teva had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.